{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:20:42Z","timestamp":1759483242843,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/00083"],"award-info":[{"award-number":["PI17\/00083"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Systemic lupus erythematosus (SLE) has been associated with atherosclerotic cardiovascular disease (CV) and an altered lipid profile. High levels of apolipoprotein C-III (ApoC3) are associated with elevated triglyceride levels and an increased risk of CV. In the present study, we aimed to study circulating ApoC3 in patients with SLE and describe its relationship with the manifestations of the disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a cross-sectional study that included 186 patients with SLE. Disease-related data, CV comorbidity, full lipid profile, and serum levels of ApoC3 were assessed. A multivariable regression analysis was performed to study how ApoC3 was related to SLE features.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Classic CV risk factors were significantly and strongly associated with circulating ApoC3. After a fully multivariable analysis that included classic CV risk factors and lipid profile molecules, SLICC damage (beta coef. 0.10 [95% <jats:italic>CI<\/jats:italic> 0.02\u20130.19] mg\/dl, 0.020) and Katz severity (beta coef. 0.11 [95% <jats:italic>CI<\/jats:italic> 0.03\u20130.19] mg\/dl, <jats:italic>p<\/jats:italic>\u2009=\u20090.011) indices and SLEDAI activity score (beta coef. 0.05 [95% <jats:italic>CI<\/jats:italic> 0.05\u20130.08] mg\/dl, <jats:italic>p<\/jats:italic>\u2009=\u20090.004) were all independently associated with higher levels of circulating ApoC3.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Among SLE patients, disease activity, severity, and disease damage are independently associated with higher ApoC3 serum levels.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02793-y","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T10:02:46Z","timestamp":1652176966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Apolipoprotein C-III in patients with systemic lupus erythematosus"],"prefix":"10.1186","volume":"24","author":[{"given":"Candelaria","family":"Mart\u00edn-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Ferrer-Moure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Carlos Quevedo-Abeledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"de Vera-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Gonz\u00e1lez-Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"S\u00e1nchez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1.","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-5267","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Ferraz-Amaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"2793_CR1","doi-asserted-by":"crossref","unstructured":"Quevedo-Abeledo JC, Caceres L, Palazuelos C, Llorca J, Gonz\u00e1lez-Gay M\u00c1, Ferraz-Amaro I. QRISK3 relation to carotid plaque is higher than that of SCORE in patients with systemic lupus erythematosus. Rheumatology [Internet]. Rheumatology (Oxford).\u00a02021;61:1408\u201316. Available from: https:\/\/www.pubmed.ncbi.nlm.nih.gov\/34240117\/. Cited 8 Sep 2021.","DOI":"10.1093\/rheumatology\/keab531"},{"key":"2793_CR2","doi-asserted-by":"publisher","first-page":"1759720X2097590","DOI":"10.1177\/1759720X20975904","volume":"12","author":"H S\u00e1nchez-P\u00e9rez","year":"2020","unstructured":"S\u00e1nchez-P\u00e9rez H, Quevedo-Abeledo JC, Tejera-Segura B, de Armas-Rillo L, R\u00faa-Figueroa I, Gonz\u00e1lez-Gay MA, et al. Proprotein convertase subtilisin\/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus. Ther Adv Musculoskelet Dis. 2020;12:1759720X20975904 Available from:  (https:\/\/pubmed.ncbi.nlm.nih.gov\/33294038\/). Cited 8 Sep 2021.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2793_CR3","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/rheumatology\/keaa038","volume":"59","author":"H S\u00e1nchez-P\u00e9rez","year":"2020","unstructured":"S\u00e1nchez-P\u00e9rez H, Quevedo-Abeledo JC, De Armas-Rillo L, Rua-Figueroa \u00cd, Tejera-Segura B, Armas-Gonz\u00e1lez E, et al. Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis. Rheumatology (Oxford). 2020;59:2847\u201356 Available from: (https:\/\/pubmed.ncbi.nlm.nih.gov\/32065639\/). Cited 8 Sep 2021.","journal-title":"Rheumatology (Oxford)"},{"key":"2793_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ijwd.2021.08.015","volume":"7","author":"E Keyes","year":"2021","unstructured":"Keyes E, Grinnell M, Jacoby D, Vazquez T, Diaz DA, Werth VP, et al. Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis. Int J Women\u2019s Dermatology. 2021;7:560\u201375 No longer published by Elsevier.","journal-title":"Int J Women\u2019s Dermatology"},{"key":"2793_CR5","doi-asserted-by":"crossref","unstructured":"Bobik A. Editorial: Apolipoprotein CIII and atherosclerosis;beyond effects on lipid metabolism [Internet]. Circulation. 2008;118:702\u20134. Available from: http:\/\/www.circ.ahajournals.org. Cited 8 Sep 2021.","DOI":"10.1161\/CIRCULATIONAHA.108.794081"},{"key":"2793_CR6","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725 Available from:  (http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9324032). Cited 30 May 2019.","journal-title":"Arthritis Rheum"},{"key":"2793_CR7","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowltz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288\u201391 Available from:  (http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11838846). Cited 10 Nov 2018.","journal-title":"J Rheumatol"},{"key":"2793_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/art.1780390303","volume":"39","author":"D Gladman","year":"1996","unstructured":"Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363\u20139 Available from: (http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8607884). Cited 10 Nov 2018.","journal-title":"Arthritis Rheum"},{"key":"2793_CR9","unstructured":"Mosca M, Bombardieri S. Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol [Internet]. 24:S-99\u2013104. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17083771. Cited 30 May 2019"},{"key":"2793_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/096120339300200210","volume":"2","author":"JD Katz","year":"1993","unstructured":"Katz JD, Senegal J-L, Rivest C, Goulet J-R, Rothfield N. A simple severity of disease index for systemic lupus erythematosus. Lupus. 1993;2:119\u201323 Available from: (http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8330033). Cited 30 May 2019.","journal-title":"Lupus"},{"key":"2793_CR11","doi-asserted-by":"crossref","unstructured":"Morgan DPE, Sturgess AD, Hennessy A, Davies MJ. Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis.\u00a0http:\/\/dx.doi.org\/101080\/10715760701684809 [Internet]. Taylor & Francis; 2009 ;41:1301\u201312. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/10715760701684809. Cited 5\u00a0Sep\u00a02021","DOI":"10.1080\/10715760701684809"},{"key":"2793_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/acr.22430","volume":"67","author":"AN Kiani","year":"2015","unstructured":"Kiani AN, Fang H, Akhter E, Quiroga C, Simpson N, Alaupovic P, et al. Apolipoprotein-containing lipoprotein subclasses and subclinical atherosclerosis in systemic lupus erythematosus. Arthritis Care Res. 2015;67:442\u20136 John Wiley and Sons Inc.","journal-title":"Arthritis Care Res"},{"key":"2793_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32\u201341 Available from:   (https:\/\/pubmed.ncbi.nlm.nih.gov\/24941082\/). Cited 8 Sep 2021.","journal-title":"N Engl J Med"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02793-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02793-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02793-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T10:09:18Z","timestamp":1652177358000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02793-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2793"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02793-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"type":"electronic","value":"1478-6362"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"assertion":[{"value":"22 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional review committees at Hospital Universitario de Canarias and Hospital Universitario Doctor Negr\u00edn, and all subjects provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. Nevertheless, Professor MA Gonzalez-Gay and Dr. Iv\u00e1n Ferraz-Amaro would like to acknowledge that they received grants\/research supports from Abbott, MSD, Jansen, and Roche and received consultation fees from company-sponsored speakers bureaus associated with Abbott, Pfizer, Roche, Sanofi, Sobi, Amgen, Celgene, and MSD.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}